Literature DB >> 12885284

Aspirin for cardiovascular disease prevention.

Joseph Hung1.   

Abstract

SECONDARY PREVENTION: Aspirin provides benefit in nearly all groups of patients with clinical manifestations of coronary heart disease. This includes patients with evolving acute myocardial infarction or after recovery from myocardial infarction, with unstable or stable angina, and those who undergo coronary artery bypass grafting or coronary angioplasty. Aspirin provides benefit in patients with peripheral arterial disease. This includes patients with acute or previous history of ischaemic stroke or transient ischaemic attack, those with lower limb arterial insufficiency, and those who undergo grafting or angioplasty of peripheral arterial vessels. PRIMARY PREVENTION: People without symptoms but at increased risk of a coronary heart disease event (> 1% annual risk) may reduce this risk by taking low-dose aspirin. However, the decision to take aspirin requires detailed consideration of individual cardiovascular risk and the potential benefit versus harm of treatment, particularly bleeding. Aspirin should only be used to prevent a cardiovascular event in association with an overall program of lifestyle measures including healthy eating, cessation of smoking, control of blood pressure and regular physical activity. ASPIRIN FOR PREVENTION: Prevention benefits of aspirin in heart disease can be achieved with doses as low as 75-150 mg daily. Unwanted effects of aspirin include stomach upsets, activation of peptic ulcers, an increased tendency to bruising, allergic reactions and increased risk of major gastrointestinal and other bleeding, including intracranial haemorrhage. In general, the risk of bleeding increases with increasing dose of aspirin and when it is used in combination with non-steroidal anti-inflammatory drugs or oral anticoagulants.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12885284     DOI: 10.5694/j.1326-5377.2003.tb05259.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  3 in total

1.  Minidose aspirin and gastrointestinal bleeding--a retrospective, case-control study in hospitalized patients.

Authors:  Boris Sapoznikov; Alex Vilkin; Marcella Hershkovici; Michal Fishman; Rami Eliakim; Yaron Niv
Journal:  Dig Dis Sci       Date:  2005-09       Impact factor: 3.199

2.  Age-related macular degeneration in a randomized controlled trial of low-dose aspirin: Rationale and study design of the ASPREE-AMD study.

Authors:  Liubov Robman; Robyn Guymer; Robyn Woods; Stephanie Ward; Rory Wolfe; James Phung; Lauren Hodgson; Galina Makeyeva; Khin Zaw Aung; Tom Gilbert; Jessica Lockery; Y-Anh Le-Pham; Suzanne Orchard; Elsdon Storey; Walter Abhayaratna; Daniel Reid; Michael E Ernst; Mark Nelson; Christopher Reid; John McNeil
Journal:  Contemp Clin Trials Commun       Date:  2017-03-27

3.  Increased susceptibility of aging gastric mucosa to injury and delayed healing: Clinical implications.

Authors:  Andrzej S Tarnawski; Amrita Ahluwalia
Journal:  World J Gastroenterol       Date:  2018-11-14       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.